Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis
NCT04469062 · Eli Lilly and Company · PHASE3 · withdrawn · last registry update 2021-05-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The trial was terminated secondary to a business decision, the original scientific question rendered moot by the external scientific community.” | – | Registry record, Eli Lilly and Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGA4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-03-03Phase 3 first posted: Biogen, Natalizumab (NCT05265728)
- 2022-02-15Results posted on the registry: University of Texas Southwestern Medical Center, Alemtuzumab (NCT03135249)
- 2021-11-11Results posted on the registry: Takeda, Vedolizumab IV (NCT03029143)
- 2021-10-21Results posted on the registry: Takeda, Vedolizumab + Adalimumab (NCT02764762)
- 2021-06-30Results posted on the registry: Takeda, Vedolizumab Placebo + Ciprofloxacin (NCT02790138)
- 2021-06-09Phase 3 first posted: Yonsei University, Vedolizumab (NCT04919252)
- 2021-04-27Results posted on the registry: Biogen, Natalizumab (NCT03283371)
- 2021-04-01Results posted on the registry: Millennium Pharmaceuticals, Inc., TAK-580 + TAK-202 (NCT02723006)
- 2021-03-03Phase 3 first posted: Takeda, Vedolizumab IV (NCT04779320)
- 2021-03-03Phase 3 first posted: Takeda, Vedolizumab (NCT04779307)
- 2021-02-04Phase 3 first posted: Takeda, Vedolizumab (NCT04738942)
- 2020-12-21Results posted on the registry: Takeda, Vedolizumab (NCT03138655)
- 2020-10-27Also stopped (withdrawn): Takeda, Caffeine + Losartan (NCT02760615)
- 2020-09-03Results posted on the registry: Medical College of Wisconsin, Tacrolimus + Vedolizumab (NCT02954159)
- 2020-09-03Also stopped (terminated): Medical College of Wisconsin, Tacrolimus + Vedolizumab (NCT02954159)
- 2020-08-12Results posted on the registry: Northwestern University, Standard treatment with a conventional drug (NCT00273364)
- 2020-06-23Results posted on the registry: Takeda, Vedolizumab SC 108 mg + Placebo (NCT02611817)
- 2020-05-14Also stopped (withdrawn): Marc Schwartz, Vedolizumab + placebo (NCT02834754)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision